Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

NCT06979531 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjögren's Syndrome

Interventions

DRUG: IMVT-1402
DRUG: Placebo

Sponsor

Immunovant Sciences GmbH